Angiotensin Type 1 Receptor Blockers in Heart Failure.

Angiotensin Type 1 Receptor Blockers in Heart Failure. Curr Drug Targets. 2019 Aug 21;: Authors: Singh KD, Karnik SS Abstract Homeostasis in the cardiovascular system is maintained by physiological functions of the Renin Angiotensin Aldosterone System (RAAS). In pathophysiological conditions, over activation of RAAS leads to an increase in the concentration of Angiotensin II (AngII) and over activation of Angiotensin Type 1 Receptor (AT1R) resulting in vasoconstriction, sodium retention and change in myocyte growth. In the heart it causes cardiac remodeling which result in left ventricular hypertrophy, dilation and dysfunction which eventually leads to Heart Failure (HF). Inhibition of RAAS using angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) have shown to significantly reduce morbidity and mortality due to HF. ACEi have been shown to have higher drug withdrawal rates due to discomfort when compared to ARBs; therefore, ARBs are the preferred choice of physicians for the treatment of HF in combination with other anti-hypertensive agents. Out of eight FDA approved ARBs, irbesartan and telmisartan are shown to have PPARĪ’ agonistic properties resulting in improved insulin intolerance. Olmesartan treatment also improves insulin sensitivity and produces anti-atherogenic and anti-inflammatory effects in patients with diabetic nephropathy. All the ARBs demonstrate beneficial effects similar to ACEi i...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research